FREMONT, Calif.--(BUSINESS WIRE)--May 31, 2006--DiscoveRx Corporation, a leading provider of GPCR and Kinase assays, today announced its new strategic vision to focus on expanding its development of a series of innovative biochemical and cell based assays. The Company's new cell based assay platform is called PathHunter(TM). This announcement immediately follows the recent penning of a global distribution agreement with GE Healthcare. That exclusive agreement provided GE with expanded access to the DiscoveRx HitHunter(TM) range of products. HitHunter(TM), and especially the cAMP product family, is a well adopted portfolio in the drug discovery screening community.
